drugset / Trial / NCT01171482

Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma

NCT01171482

Phase 2 Terminated 5 enrolled Seoul National University Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is to compare the efficacy of sorafenib to 5-fluorouracil/mitomycin in HCC patients with pulmonary metastasis whose intrahepatic tumors has been controlled with locoregional therapies.

Timeline

Start
2015-11
Primary completion
2016-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitomycin C Other / unclassified 4 mg Intravenous
Comparator Sorafenib Small molecule 400 mg Oral
Subject fluorouracil Small molecule 15 mg/kg Intravenous